Want to see DNA full AI Analyst Report?
DNA Stock Chart & Stats
$7.54
$0.09(1.22%)
At close: 4:00 PM EDT
$7.54
$0.09(1.22%)
Day’s Range― - ―
52-Week Range$5.37 - $18.22
Previous Close$7.4
Volume576.45K
Average Volume (3M)2.92M
Market Cap
$678.12M
Enterprise Value$714.39M
Total Cash (Recent Filing)$302.16M
Total Debt (Recent Filing)$404.11M
Price to Earnings (P/E)―
Beta3.20
Next Earnings
Nov 16, 2026EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.02
Shares Outstanding55,383,810
10 Day Avg. Volume4,707,715
30 Day Avg. Volume2,915,701
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.91
Price to Sales (P/S)2.71
P/FCF Ratio-2.58
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue6.39
Enterprise Value/Gross Profit7.97
Enterprise Value/Ebitda-2.95
Forecast
1Y Price Target
$8.00Price Target Upside6.10% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)-4.33
Revenue Forecast (FY)$85.07M
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginThe very high gross margin suggests Ginkgo can retain substantial value from revenue generated by its platform and services. If revenue scales, this economic profile could support operating leverage, although the company still must reduce its large fixed cost base to convert gross profit into sustainable earnings.
Liquidity And Contractual DisciplineA sizeable liquidity position gives Ginkgo time to execute its platform strategy and fund autonomous-lab investment. The Google Cloud renegotiation also lowers future contractual obligations, improving cash planning and preserving flexibility while management works toward lower ongoing cash consumption.
Cost-Competitive ADME ProductADME-One’s substantial price advantage and reported agreement with industry datasets create a credible pathway to customer adoption in a large research workflow. A differentiated, productized service could broaden Ginkgo’s commercial reach and improve platform utilization beyond individual development programs.
Bears Say
Severe Revenue ContractionThe depth and persistence of the revenue decline indicate that customer program volume, commercialization timing, or both remain insufficient to support the existing business footprint. Continued contraction would weaken operating leverage, make fixed costs harder to absorb, and delay the path toward self-funded growth.
Large Losses And Cash BurnVery large operating losses and recurring negative free cash flow show that Ginkgo’s platform is not yet financially self-sustaining. Ongoing cash consumption requires continued cost reductions, revenue growth, or external financing, limiting strategic flexibility and increasing execution pressure over the next several quarters.
Execution And Product Maturity RiskUnresolved software and automation issues can constrain throughput, reliability, and the pace at which Nebula deployments become repeatable commercial offerings. Until scheduler robustness and variability handling improve, operational execution may limit customer satisfaction, utilization, and the scalability of Ginkgo’s lab platform.
Ginkgo Bioworks Holdings News
DNA FAQ
What was Ginkgo Bioworks Holdings’s price range in the past 12 months?
Ginkgo Bioworks Holdings lowest stock price was $5.37 and its highest was $18.22 in the past 12 months.
What is Ginkgo Bioworks Holdings’s market cap?
Ginkgo Bioworks Holdings’s market cap is $678.12M.
When is Ginkgo Bioworks Holdings’s upcoming earnings report date?
Ginkgo Bioworks Holdings’s upcoming earnings report date is Nov 16, 2026 which is in 26 days.
How were Ginkgo Bioworks Holdings’s earnings last quarter?
Ginkgo Bioworks Holdings released its earnings results on Aug 05, 2026. The company reported -$0.75 earnings per share for the quarter, beating the consensus estimate of -$0.895 by $0.145.
Is Ginkgo Bioworks Holdings overvalued?
According to Wall Street analysts Ginkgo Bioworks Holdings’s price is currently Undervalued.
Does Ginkgo Bioworks Holdings pay dividends?
Ginkgo Bioworks Holdings does not currently pay dividends.
What is Ginkgo Bioworks Holdings’s EPS estimate?
Ginkgo Bioworks Holdings’s EPS estimate is -0.68.
How many shares outstanding does Ginkgo Bioworks Holdings have?
Ginkgo Bioworks Holdings has 55,383,810 shares outstanding.
What happened to Ginkgo Bioworks Holdings’s price movement after its last earnings report?
Ginkgo Bioworks Holdings reported an EPS of -$0.75 in its last earnings report, beating expectations of -$0.895. Following the earnings report the stock price went down -9.285%.
Which hedge fund is a major shareholder of Ginkgo Bioworks Holdings?
Currently, no hedge funds are holding shares in DNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ginkgo Bioworks Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$8.00 (6.10% Upside)
$8.00 (6.10% Upside)
Blogger Sentiment
Neutral
DNA Sentiment 78%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 24.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.5%
Last 30 Days ▲ 10.6%
Last 30 Days ▲ 10.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-24.00%
12-Months-Change
Fundamentals
Return on Equity
-60.21%
Trailing 12-Months
Asset Growth
-19.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
DNA Company Deck
DNA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced significant strategic and operational progress with near-term financial headwinds. Positives include major academic and national lab contracts, rapid expansion and scale demonstration of Nebula, a competitive ADME product with strong price/performance and a solid cash position plus a reduced long‑term Google Cloud commitment. Negatives include steep year‑over‑year revenue declines, wider GAAP losses and worse adjusted EBITDA in Q2, elevated quarter‑specific cash burn and ongoing excess lease costs. Management emphasizes cost discipline, a shift toward investing in autonomous labs and predictable cash burn guidance for 2026, but revenue recognition timing for automation deals and the need to further mature operations create near‑term uncertainty.View all DNA earnings summariesDNA Revenue Breakdown
57.08% Cell Engineering
42.92% Biosecurity
DNA Stock 12 Month Forecast
Average Price Target
$8.00
▲(6.10% Upside)
Technical Analysis
Niagen Bioscience
―
Monopar Therapeutics Inc
―
Lyell Immunopharma
―
Jade Biosciences
―
AbSci
―
Ownership Overview
2.83% Insiders
15.30% Mutual Funds
1.91% Other Institutional Investors
64.19% Public Companies and
Individual Investors